News
IBIO
2.640
+7.76%
0.190
Weekly Report: what happened at IBIO last week (1111-1115)?
Weekly Report · 5d ago
iBio, Inc. Reports Financial Results for the Quarter Ended September 30, 2024
Press release · 11/13 00:49
iBio GAAP EPS of -$0.46 in-line
Seeking Alpha · 11/12 23:13
iBio Q1 EPS $(0.46) Beats $(0.48) Estimate
Benzinga · 11/12 21:52
iBio reports Q1 EPS (46c), consensus (48c)
TipRanks · 11/12 21:44
Press Release: iBio Reports Fiscal First Quarter 2025 Financial Results
Dow Jones · 11/12 21:05
iBio Reports Fiscal First Quarter 2025 Financial Results
Barchart · 11/12 15:05
Weekly Report: what happened at IBIO last week (1104-1108)?
Weekly Report · 11/11 09:42
Earnings week ahead: DIS, BABA, JD, CSCO, HD, OXY, SU, SHOP, AMAT, SPOT, and more
Seeking Alpha · 11/10 13:01
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching
Barchart · 11/08 01:10
Weekly Report: what happened at IBIO last week (1028-1101)?
Weekly Report · 11/04 09:41
Weekly Report: what happened at IBIO last week (1021-1025)?
Weekly Report · 10/28 09:38
iBio Unveils AI-Driven Antibody Discovery Strategy
TipRanks · 10/23 13:28
Weekly Report: what happened at IBIO last week (1014-1018)?
Weekly Report · 10/21 09:38
Weekly Report: what happened at IBIO last week (1007-1011)?
Weekly Report · 10/14 09:46
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/10 15:10
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/09 15:00
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/07 16:31
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 10/07 12:08
Weekly Report: what happened at IBIO last week (0930-1004)?
Weekly Report · 10/07 09:43
More
Webull provides a variety of real-time IBIO stock news. You can receive the latest news about Ibio through multiple platforms. This information may help you make smarter investment decisions.
About IBIO
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.